Becton Dickinson BDX
-
Dr. Robin Smith Explaining NeoStem: A True Value Play
By Brian Nichols : My goal moving forward in a very volatile and uncertain economy is to invest in stocks that I believe to be value investments. So far in 2012, I have written several articles expressing my beliefs that the absolute best value in the market is in the biotechnology space, and in ...
-
5 Reasons To Buy NeoStem And 2 Catalysts
By The Swiss Trader : NeoStem ( NBS ) is a diversified stem cell technology company that is focusing its broad expertise and resources on the development of high-value cellular therapies aimed at impacting outcomes of serious diseases with an unmet medical need. The company expanded its core ...
-
Becton , Dickinson and Co: Dividend Stock Analysis
… detailed quantitative analysis of Becton , Dickinson and Co . ( BDX ). Below are some highlights ..... analysis: Company Description: Becton , Dickinson and Co . provides a wide range of ..... E Price 4. Graham Number BDX is trading at a discount to …
-
What's Wrong With Covidien?
By Stephen Simpson : You would think that a company posting roughly double the industry average revenue growth rate and solid margins should be one of the more highly-valued companies in the sector. Alas, that's not the case with Covidien ( COV ). While I don't want to leave readers with the ...
-
Trading Margins For Growth Isn't Going To Help Becton Dickinson
By Stephen Simpson : Becton Dickinson ( BDX ) has been a single-digit grower for most of the past decade, and that really hasn't seemed to bother anybody. There's …
-
Hologic Must Make The Third Time A Charm
By Stephen Simpson : Big deals understandably make investors nervous, but when the buyer in question already has a record and reputation for overpaying in deals and failing to reap all of the promised benefits, it's so much the worse. That's the burden on Hologic ( HOLX ) now that it has announced
-
Becton Dickinson Raises Guidance After Good 2Q; Our Fair Value Unchanged
Becton Dickinson BDX reported second-quarter results that were slightly better than expected in medical and diagnostics groups, but below our and …
-
Notable earnings before Tuesday’s open: [[ACI]], [[ADM]], [[ADP]], [[AGCO]], [[AMG]], [[ARW]], [[AVP]], [[ BDX ]], [[BIIB]], [[BP]], [[CCJ]], [[CIE]], [[CMI]], [[DPZ]], [[ECL]], [[EMR]], [[ENDP]], ...
Notable earnings before Tuesday’s open: ACI , ADM , ADP , AGCO , AMG , ARW , AVP , BDX , BIIB , BP , CCJ , CIE , CMI , DPZ , ECL , EMR , ENDP , FE , FWLT , HCP , HRS , HSP , HUN , LM , MLM , MMC , NI , PFE , PLD , SIRI …
-
Corning From Another Perspective
By Gregory M. Lemelson : On Dec. 19, 2011, we began purchasing shares of Corning ( GLW ) for investor accounts; these purchases were made at an average price of $12.73 per share. Unfortunately, we didn't have time to write an article explaining all of the reasons why we felt Corning represented a
-
3 Healthcare Stocks Looking Undervalued And With Solid Profitability
By ZetaKap : If you are interested in gaining exposure to healthcare companies, are looking for undervalued stocks and for ways to dip deeper into a company's profitability, you'll probably like this list. The Price/Book Value Ratio is a great price-multiple valuation metric to find companies that